| INTRODUCTION
The achievement of functional cure for chronic hepatitis B (CHB) infection remains difficult due to a persistent infection of hepatocytes with covalently closed circular DNA (cccDNA). 1, 2 CccDNA is a minichromosome that serves as a transcription template for hepatitis B virus (HBV) antigen and virion production. Nucleos(t)ide analogue (NA) therapy only marginally reduces levels of cccDNA such that cccDNA depletion would require years of NA treatment. 3, 4 NA therapy effectively suppresses the HBV up to 8 years with few side-effects, but serological response rates remain low. The discontinuation of NA therapy leads to frequent virological relapse and patients therefore require long-term, if not indefinite NA therapy. [5] [6] [7] [8] [9] [10] In contrast, a finite course of pegylated interferon (PEG-IFN) achieves more sustained immune response than NA therapy. 9, 11, 12 PEG-IFN is also able to directly target cccDNA and induce cccDNA decline in combination with NA therapy. 13, 14 PEG-IFN monotherapy, however, induces sustained response in only 30%-40% of patients and has limited tolerability. 15, 16 These limitations of CHB therapy have led to the evaluation of various treatment combinations of NAs and PEG-IFN to maximise response rates, among which is the strategy of adding PEG-IFN to NA treatment (PEG-IFN add-on). One of the rationales for the PEG-IFN add-on strategy is that long-term NA treatment enables partial restoration of the liver-specific immunology of both the adaptive (Tcells) and innate immune system (natural killer cells). [17] [18] [19] [20] Viral load suppression could thus increase the immunomodulatory effect of PEG-IFN therapy resulting in increased HBsAg loss and HBeAg loss or accelerated HBsAg decline rates.
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Several randomized controlled trials (RCT) employed a PEG-IFN add-on strategy in HBeAg positive and negative patients on longterm NA monotherapy. [21] [22] [23] PEG-IFN add-on increased HBeAg seroconversion and viral antigen decline, but primary efficacy endpoints were not reached, possibly because of insufficient power or because the effect was limited to a subgroup of patients only. Clinical practice could benefit substantially if these responsive patients can be identified at the start of PEG-IFN therapy with readily available laboratory markers. Other remaining issues concern the optimal duration of PEG-IFN add-on and of NA pretreatment.
We therefore evaluated whether PEG-IFN add-on to ETV treatment increases serological response compared to ETV monotherapy in CHB, and whether the duration of ETV pretreatment or the length of PEG-IFN addition therapy influenced response. To this purpose,
we performed an analysis in a large HBeAg positive CHB population that was previously treated in two global RCTs.
| MATERIALS AND METHODS

| Combined study design
We conducted a post hoc analysis of two international RCTs (ARES and PEGON; registered at ClinicalTrials.gov, Identifier: NCT00877760, NCT01532843). 21, 23 Detailed inclusion and exclusion criteria have been previously described. In short, patients with CHB were eligible if they were HBeAg positive at randomization (baseline) and had a serum Several patients within the ARES study did not reach the designated primary endpoint at the end of treatment. These patients were allowed to enrol in the subsequent PEGON trial and were then randomized again to PEG-IFN add-on or ETV monotherapy. This study was approved by local ethics boards of all centres and performed in concordance with Good Clinical Practice guidelines and the Declaration of Helsinki. All patients provided written consent.
| Study endpoints
Response was defined as combined HBeAg loss with HBV DNA <200 IU/mL at EOF. We analysed the modified intention-to-treat population, which includes all patients who received at least one dose of the allocated treatment after baseline. Patients were considered non-responders in case of missing HBeAg status or HBV DNA at EOF. To assess the potential for functional cure, as studied with therapeutic compounds now in development, we also investigated specific other virological and serological outcomes ( Cut-off values for HBV DNA and HBsAg at baseline were evaluated to find clinically useful starting rules for PEG-IFN add-on.
HBsAg levels were dichotomised at thresholds between 2.7 and 5.0 log IU/mL in steps of 0.1. HBV DNA was categorised at 50, 100, 500, and 1000 IU/mL. The likelihood-ratio test and sum of log-likelihood ratios of the two treatment groups were calculated. We selected optimal cut-off values based on a minimum response difference of 15% between add-on and monotherapy; a significant likelihood ratio test of add-on vs monotherapy below the cut-offs, but not above; and the lowest sum of likelihood ratios. For each threshold receiver operating characteristic curves were constructed and AUCs were calculated and compared to each other. Furthermore, a sensitivity analysis was performed among non-responding patients within the ARES study who subsequently received retreatment in the PEGON study by modelling the correlated data in a generalised estimating equation. 25 Analyses were performed in SPSS (v. 22.0, Chicago, IL) and SAS v. 11.2 (SAS Institute Inc, Cary, NC). Two-sided P < 0.05 were considered significant.
| RESULTS
| Patient population
A total of 234 patients met the inclusion criteria. Excluded were five patients assigned PEG-IFN add-on and 10 assigned ETV monotherapy who had achieved HBeAg loss at baseline (during ETV pretreatment). At baseline, 118 patients were allocated to PEG-IFN add-on and 116 patients continued ETV monotherapy. Baseline characteristics were comparable between the two groups ( Table 1 ). The mean age was 33 (SD 9) years, the majority of patients were male and of HBeAg loss combined with HBV DNA <200 IU/mL? Table S1 .
| Response
Response was reached in 38/118 (33%) patients allocated to add-on therapy and in 23/116 (20%) patients with ETV monotherapy (P = 0.03; Figure 2 and Table 2 ). Other serological, virological, and biochemical outcomes are reported in The two sensitivity analyses (cohort without 36 retreated non-responders and whole cohort with adjustment for correlated data)
were consistent with our findings indicating that PEG-IFN add-on significantly increased response to ETV monotherapy (Table S2 ).
| HBsAg decline and loss
HBsAg decline >0.5 log IU/mL occurred more often in the PEG-IFN add-on group compared to the ETV monotherapy group at EOF (25 Similarly, disease remission (combined HBeAg loss, HBV DNA <200 IU/mL and ALT normalisation at EOF) in PEG-IFN add-on vs ETV monotherapy was achieved by 12/16 vs 2/2 patients (P = 0.42). HBsAg at baseline ( Figure S1 ).
| Response prediction
| Response-guided therapy using HBV DNA and HBsAg
To establish clinical starting rules for PEG-IFN add-on, the relationship between different cut-off values of HBsAg and HBV DNA at baseline and likelihood of response was evaluated ( Figure S2 and Table S3 ). As previous use of PEG-IFN was strongly associated with a lack of response, we evaluated all PEG-IFN naive patients (198/
[85%]). Based on this analysis, PEG-IFN naive patients with an
HBsAg level below 4000 IU/mL (3.6 log) and HBV DNA level below 50 IU/mL (1.7 log) at baseline achieved the largest gain in probability of response with PEG-IFN add-on compared to ETV monotherapy (70% vs 34%, P = 0.01; Figure 3 ). Patients who met one of the above criteria achieved a moderate gain in response from PEG-IFN add-on, compared to ETV monotherapy (44% vs 17%; P = 0.02).
Above the proposed HBsAg and HBV DNA cut-off levels, response was very low and not significantly different between treatment groups (PEG-IFN add-on vs ETV monotherapy: 9.3% vs 5.9%; P = 0.58). The cut-off values combined had an AUC of 0.79 (95% CI 0.72-0.86) for probability of response.
| DISCUSSION
In this combined analysis of two global RCTs, PEG-IFN add-on to ETV increased response compared to ETV monotherapy in HBeAg positive patients with CHB. Response was 33% for add-on patients vs 20% for ETV monotherapy. HBeAg seroconversion rates at EOF were also significantly higher in add-on patients. The response to PEG-IFN add-on was especially high (up to 70%) among patients who were naive to PEG-IFN therapy and had low HBV DNA (<50 IU/mL) and HBsAg levels (<4000 IU/mL) at the start of PEG-IFN therapy. (21) a HBV DNA groups: <lower limit of detection (<20 IU/mL); 20-100 IU/mL; 100-1000 IU/mL; ≥1000 IU/mL. *P < 0.05. values, because of the low probability of response. Our HBsAg threshold is concordant with a threshold found in another study which showed that HBsAg <1500 IU/mL predicted response. 28 Moreover, the higher and thus more lenient HBsAg cut-off value established in this study would allow practitioners to identify even more candidates for PEG-IFN add-on at an earlier stage in their disease course. None of the previous add-on studies provided a comprehensive grid search to establish response-guided therapy. Apart from response, the side effects and cost-effectiveness should to be taken into consideration when deciding on a treatment strategy.
In recent RCTs that compared PEG-IFN add-on to continuing NA monotherapy, HBsAg decline rates were significantly higher in the add-on group, yet the primary endpoints (HBsAg loss at week 96;
combined HBeAg loss with HBV DNA <200 IU/mL at week 96) were not reached, potentially due to a type II error. [21] [22] [23] In the ARES study response was achieved in 19% of patients in the add-on arm vs 10% in the monotherapy arm (P = 0.095); declines in HBsAg, HBeAg, and HBV DNA were also larger in the add-on group (all P < 0.001). 21 Uncontrolled studies in HBeAg positive and negative patients reported similar findings. The endpoint of HBeAg seroclearance is clinically relevant because it is associated with a lower risk of HCC and improved survival. 9 Since only a subset of patients stopped ETV therapy after receiving consolidation therapy the durability of sustained response after treatment discontinuation could not be studied in further detail.
Long-term follow-up studies could focus on the effect on HBsAg loss or development of important clinical outcomes (decompensation, HCC and death), although such studies will be difficult to perform.
Due to the fact that part of the patients had received long-term HBV suppressive therapy HBV genotype and cirrhosis status was not known for some patients. Nevertheless, the sensitivity analyses performed to adjust for these partially missing baseline characteristics also showed higher response and HBsAg decline achieved by PEG-IFN add-on compared to ETV monotherapy. It is important that our findings will be validated in new PEG-IFN add-on studies.
In conclusion, PEG-IFN add-on to ETV therapy was associated with a higher probability of response and HBeAg seroconversion compared to ETV monotherapy in HBeAg-positive CHB. Response was highest in patients who were naive to PEG-IFN therapy with levels of HBsAg below 4000 IU/mL and HBV DNA below 50 IU/mL. In particular these patients should be offered PEG-IFN add-on therapy. 
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